Patrick G. Enright

October 17, 2026

JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.

October 10, 2026

Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.

October 16, 2026

Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.

October 13, 2026

ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.

September 26, 2026

BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.